Randolf Kerschbaumer, Michael Thiele and Alexander Schinagl (OncoOne)

For­mer Shire ex­ecs set up shop to take a shot at 'un­der the radar' can­cer tar­get

In De­cem­ber 2016, Shire aban­doned a can­cer drug tar­get­ing oxMIF it had swal­lowed as part of its $32 bil­lion buy­out of Bax­al­ta ear­li­er that year. Now for­mer ex­ec­u­tives of the two com­pa­nies have set up their own shop in Aus­tria — bank­ing on that same tar­get.

The com­pa­ny, chris­tened On­coOne, has scored €13 mil­lion in a Se­ries A round. With 8 em­ploy­ees, in­clud­ing its 3 founders, the com­pa­ny will use the in­jec­tion to take its com­pounds — de­signed to ad­dress pan­cre­at­ic, col­orec­tal, lung and ovar­i­an can­cer — in­to the clin­ic by 2022.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.